2:I[2885,["231","static/chunks/231-9e11bdfe3b664aec.js","669","static/chunks/app/asx/%5Bticker%5D/page-bf9260c50397686f.js"],"default"]
3:I[231,["231","static/chunks/231-9e11bdfe3b664aec.js","669","static/chunks/app/asx/%5Bticker%5D/page-bf9260c50397686f.js"],""]
4:I[9275,[],""]
6:I[1343,[],""]
7:I[8173,["231","static/chunks/231-9e11bdfe3b664aec.js","896","static/chunks/896-78f6f35c40d7ae60.js","391","static/chunks/391-646e1fce9b8930c4.js","185","static/chunks/app/layout-6784eb5ba9ddff8d.js"],"Image"]
8:I[4019,["231","static/chunks/231-9e11bdfe3b664aec.js","896","static/chunks/896-78f6f35c40d7ae60.js","391","static/chunks/391-646e1fce9b8930c4.js","185","static/chunks/app/layout-6784eb5ba9ddff8d.js"],"default"]
5:["ticker","PME","d"]
0:["eCy3-J0ZIPs_GGnvutRNr",[[["",{"children":["asx",{"children":[["ticker","PME","d"],{"children":["__PAGE__?{\"ticker\":\"PME\"}",{}]}]}]},"$undefined","$undefined",true],["",{"children":["asx",{"children":[["ticker","PME","d"],{"children":["__PAGE__",{},[["$L1",["$","div",null,{"className":"space-y-12","children":[["$","script",null,{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What does PME do?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Pro Medicus Limited develops and provides diagnostic imaging software and services, including patient engagement tools and imaging data management solutions, primarily to the healthcare sector.\"}},{\"@type\":\"Question\",\"name\":\"Is PME a good investment?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"PME offers a compelling growth story with its strong market position and growth prospects. However, investors should weigh this against the speculative nature of tech stocks, potential competition, and regulatory risks.\"}},{\"@type\":\"Question\",\"name\":\"What drives PME's share price?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Key drivers include contract wins/losses, innovation in product offerings, international expansion success, global demand for digital health solutions, and broader tech sector trends.\"}}]}"}}],["$","section",null,{"className":"grid gap-8 lg:grid-cols-[1.6fr_0.8fr]","children":[["$","div",null,{"className":"space-y-6","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.3em] text-blue-300","children":"Health Care"}],["$","h1",null,{"className":"mt-3 font-display text-3xl font-semibold","children":["Pro Medicus Limited"," (","PME",")"]}],["$","p",null,{"className":"mt-4 text-sm text-slate-300","children":"Pro Medicus Limited (ASX: PME) is a global leader in medical imaging software, specialising in its high-performance Visage 7 enterprise imaging platform. The company provides innovative solutions for the management, viewing, and analysis of medical images, serving large hospitals and health systems worldwide. Its core business revolves around long-term, high-value contracts for its cloud-based software, positioning it strongly in the evolving healthcare technology landscape."}],["$","div",null,{"className":"mt-6 grid gap-4 sm:grid-cols-2","children":[["$","div",null,{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-xs text-slate-500","children":"Market Cap"}],["$","p",null,{"className":"mt-2 text-lg font-semibold","children":"A$17.2B"}]]}],["$","div",null,{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-xs text-slate-500","children":"Shares on Issue"}],["$","p",null,{"className":"mt-2 text-lg font-semibold","children":"N/A"}]]}]]}],["$","div",null,{"className":"mt-6 flex flex-wrap gap-3 text-xs text-slate-400","children":[["$","a",null,{"href":"","className":"rounded-full border border-white/10 px-3 py-1","children":"Company Website"}],["$","span",null,{"className":"rounded-full border border-white/10 px-3 py-1","children":"AI coverage updated hourly"}],["$","span",null,{"className":"rounded-full border border-white/10 px-3 py-1","children":"Data from ASX filings"}]]}]]}],["$","$L2",null,{"ticker":"PME"}],["$","section",null,{"className":"space-y-6","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h2",null,{"className":"font-display text-xl font-semibold","children":"AI Analysis"}],["$","div",null,{"className":"mt-4 space-y-4 text-sm text-slate-300","children":[["$","p","Pro Medicus Limited (ASX: PME) is a prominent A$17.2 billion large-cap health care technology company renowned for its cutting-edge Visage 7 imaging platform, which enables efficient management and viewing of medical images. Despite its robust fundamentals, including a high-margin, recurring revenue model and a sticky client base, the stock has seen a challenging period, with its share price currently at A$157.62, reflecting a -21.1% performance over the last year. Investors are keenly awaiting the upcoming HY Results release on 19 January 2026, which will provide crucial insights into its operational performance and future guidance. Other recent notifications regarding unquoted securities are likely routine administrative updates.",{"children":"Pro Medicus Limited (ASX: PME) is a prominent A$17.2 billion large-cap health care technology company renowned for its cutting-edge Visage 7 imaging platform, which enables efficient management and viewing of medical images. Despite its robust fundamentals, including a high-margin, recurring revenue model and a sticky client base, the stock has seen a challenging period, with its share price currently at A$157.62, reflecting a -21.1% performance over the last year. Investors are keenly awaiting the upcoming HY Results release on 19 January 2026, which will provide crucial insights into its operational performance and future guidance. Other recent notifications regarding unquoted securities are likely routine administrative updates."}],["$","p","Operating within the dynamic Health Care sector, PME benefits significantly from the ongoing digital transformation in medical imaging and the increasing adoption of cloud-based solutions globally. The company holds a strong competitive position due to its superior technology, scalability, and proven ability to secure multi-year contracts with major healthcare institutions, particularly in the lucrative US market. Key drivers for its continued success include expanding its client base, the migration of existing clients to its cloud offerings, and potential advancements in integrating artificial intelligence into its platform.",{"children":"Operating within the dynamic Health Care sector, PME benefits significantly from the ongoing digital transformation in medical imaging and the increasing adoption of cloud-based solutions globally. The company holds a strong competitive position due to its superior technology, scalability, and proven ability to secure multi-year contracts with major healthcare institutions, particularly in the lucrative US market. Key drivers for its continued success include expanding its client base, the migration of existing clients to its cloud offerings, and potential advancements in integrating artificial intelligence into its platform."}],["$","p","Looking ahead, PME's outlook remains positive, underpinned by structural tailwinds in medical imaging and its strong market position. Potential catalysts for the stock include further significant contract wins, successful execution of its cloud migration strategy, and a strong performance indicated in the forthcoming HY results. Given its large-cap status and premium valuation, investors should closely monitor growth in new contract signings, client retention rates, and any shifts in market sentiment towards high-growth technology stocks, alongside the company's ability to maintain its innovation edge and operational efficiency.",{"children":"Looking ahead, PME's outlook remains positive, underpinned by structural tailwinds in medical imaging and its strong market position. Potential catalysts for the stock include further significant contract wins, successful execution of its cloud migration strategy, and a strong performance indicated in the forthcoming HY results. Given its large-cap status and premium valuation, investors should closely monitor growth in new contract signings, client retention rates, and any shifts in market sentiment towards high-growth technology stocks, alongside the company's ability to maintain its innovation edge and operational efficiency."}]]}]]}],["$","div",null,{"className":"grid gap-6 lg:grid-cols-2","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"flex items-center gap-2 text-sm font-semibold text-emerald-300","children":"Bull Case"}],["$","ul",null,{"className":"mt-4 space-y-2 text-sm text-slate-300","children":[["$","li","Successful expansion of Xercise and MedMovie into the U.S. and European markets could significantly boost revenue.",{"children":["• ","Successful expansion of Xercise and MedMovie into the U.S. and European markets could significantly boost revenue."]}],["$","li","Continued innovation in AI-powered imaging solutions could lead to market share gains.",{"children":["• ","Continued innovation in AI-powered imaging solutions could lead to market share gains."]}],["$","li","Potential for strategic acquisitions to enhance its product portfolio and reach.",{"children":["• ","Potential for strategic acquisitions to enhance its product portfolio and reach."]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"flex items-center gap-2 text-sm font-semibold text-red-300","children":"Bear Case"}],["$","ul",null,{"className":"mt-4 space-y-2 text-sm text-slate-300","children":[["$","li","Intense competition from global health tech giants could limit market share expansion.",{"children":["• ","Intense competition from global health tech giants could limit market share expansion."]}],["$","li","Regulatory challenges in new markets (e.g., U.S., EU) might slow international growth plans.",{"children":["• ","Regulatory challenges in new markets (e.g., U.S., EU) might slow international growth plans."]}],["$","li","Dependence on long-term contracts poses risks if major clients opt not to renew.",{"children":["• ","Dependence on long-term contracts poses risks if major clients opt not to renew."]}]]}]]}]]}]]}],null,["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"Recent Announcements"}],["$","div",null,{"className":"mt-4 space-y-3 text-sm text-slate-300","children":[["$","div","0",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","div",null,{"className":"flex flex-wrap items-center gap-2","children":[["$","p",null,{"className":"font-semibold text-white","children":"PME HY Results release date and webcast briefing"}],false]}],["$","div",null,{"className":"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500","children":[["$","span",null,{"children":"19 Jan 2026"}],["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5","children":"General"}]]}],""]}],["$","div","1",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","div",null,{"className":"flex flex-wrap items-center gap-2","children":[["$","p",null,{"className":"font-semibold text-white","children":"Notification regarding unquoted securities - PME"}],false]}],["$","div",null,{"className":"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500","children":[["$","span",null,{"children":"13 Jan 2026"}],["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5","children":"Capital Structure"}]]}],""]}],["$","div","2",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","div",null,{"className":"flex flex-wrap items-center gap-2","children":[["$","p",null,{"className":"font-semibold text-white","children":"Notification of cessation of securities - PME"}],false]}],["$","div",null,{"className":"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500","children":[["$","span",null,{"children":"13 Jan 2026"}],["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5","children":"Capital Structure"}]]}],""]}],["$","div","3",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","div",null,{"className":"flex flex-wrap items-center gap-2","children":[["$","p",null,{"className":"font-semibold text-white","children":"Notification regarding unquoted securities - PME"}],false]}],["$","div",null,{"className":"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500","children":[["$","span",null,{"children":"13 Jan 2026"}],["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5","children":"Capital Structure"}]]}],""]}],["$","div","4",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","div",null,{"className":"flex flex-wrap items-center gap-2","children":[["$","p",null,{"className":"font-semibold text-white","children":"Notification regarding unquoted securities - PME"}],false]}],["$","div",null,{"className":"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500","children":[["$","span",null,{"children":"13 Jan 2026"}],["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5","children":"Capital Structure"}]]}],""]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"FAQs"}],["$","div",null,{"className":"mt-4 space-y-3 text-sm text-slate-300","children":[["$","div","What does PME do?",{"className":"border-b border-white/5 pb-3","children":[["$","p",null,{"className":"font-semibold text-white","children":"What does PME do?"}],["$","p",null,{"className":"text-slate-400","children":"Pro Medicus Limited develops and provides diagnostic imaging software and services, including patient engagement tools and imaging data management solutions, primarily to the healthcare sector."}]]}],["$","div","Is PME a good investment?",{"className":"border-b border-white/5 pb-3","children":[["$","p",null,{"className":"font-semibold text-white","children":"Is PME a good investment?"}],["$","p",null,{"className":"text-slate-400","children":"PME offers a compelling growth story with its strong market position and growth prospects. However, investors should weigh this against the speculative nature of tech stocks, potential competition, and regulatory risks."}]]}],["$","div","What drives PME's share price?",{"className":"border-b border-white/5 pb-3","children":[["$","p",null,{"className":"font-semibold text-white","children":"What drives PME's share price?"}],["$","p",null,{"className":"text-slate-400","children":"Key drivers include contract wins/losses, innovation in product offerings, international expansion success, global demand for digital health solutions, and broader tech sector trends."}]]}]]}]]}]]}],["$","div",null,{"className":"space-y-6","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-semibold","children":"Key Metrics"}],["$","div",null,{"className":"mt-4 space-y-4 text-sm","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Share Price"}],["$","span",null,{"className":"font-semibold","children":["A$","157.62"]}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"1Y Performance"}],["$","span",null,{"className":"font-semibold text-red-400","children":["-21.1","%"]}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Market Cap"}],["$","span",null,{"className":"font-semibold","children":"A$17.2B"}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Shares on Issue"}],["$","span",null,{"className":"font-semibold","children":"N/A"}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Sector"}],["$","span",null,{"className":"font-semibold","children":"Health Care"}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"IPO Date"}],["$","span",null,{"className":"font-semibold","children":"10/10/2000"}]]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"Related Stocks"}],["$","div",null,{"className":"mt-4 space-y-4","children":[["$","$L3",null,{"href":"/asx/CSL","className":"group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","div",null,{"children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.2em] text-slate-500","children":"Health Care"}],["$","h3",null,{"className":"mt-2 font-display text-lg font-semibold","children":["CSL",["$","span",null,{"className":"ml-2 text-sm text-slate-400","children":"CSL Ltd"}]]}]]}],["$","div",null,{"className":"text-right","children":[["$","p",null,{"className":"text-sm text-slate-300","children":["A$","180.50"]}],["$","p",null,{"className":"text-xs font-semibold text-red-400","children":["-27.6","% 1Y"]}]]}]]}],["$","p",null,{"className":"mt-4 text-sm text-slate-400","children":"CSL Ltd is a global biopharmaceutical company specialising in the development, manufacture, and marketing of plasma-derived therapies, vaccines, and recombinant technologies. It holds a dominant market position in critical areas such as immunology, haematology, and influenza prevention through its CSL Behring and Seqirus businesses. The company's core operations involve a vast global plasma collection network and advanced manufacturing facilities to produce life-saving treatments."}],["$","div",null,{"className":"mt-4 flex items-center justify-between text-xs text-slate-500","children":[["$","span",null,{"children":["Market cap ","A$87.9B"]}],["$","span",null,{"className":"text-blue-300","children":"View analysis"}]]}]]}],["$","$L3",null,{"href":"/asx/PNV","className":"group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","div",null,{"children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.2em] text-slate-500","children":"Health Care"}],["$","h3",null,{"className":"mt-2 font-display text-lg font-semibold","children":["PNV",["$","span",null,{"className":"ml-2 text-sm text-slate-400","children":"Polynovo Ltd"}]]}]]}],["$","div",null,{"className":"text-right","children":[["$","p",null,{"className":"text-sm text-slate-300","children":["A$","0.92"]}],["$","p",null,{"className":"text-xs font-semibold text-red-400","children":["-20.1","% 1Y"]}]]}]]}],["$","p",null,{"className":"mt-4 text-sm text-slate-400","children":"Polynovo manufactures innovative wound care products used in burns, trauma, and reconstructive surgery."}],["$","div",null,{"className":"mt-4 flex items-center justify-between text-xs text-slate-500","children":[["$","span",null,{"children":["Market cap ","A$687M"]}],["$","span",null,{"className":"text-blue-300","children":"View analysis"}]]}]]}],["$","$L3",null,{"href":"/asx/1AD","className":"group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","div",null,{"children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.2em] text-slate-500","children":"Health Care"}],["$","h3",null,{"className":"mt-2 font-display text-lg font-semibold","children":["1AD",["$","span",null,{"className":"ml-2 text-sm text-slate-400","children":"Adalta Limited"}]]}]]}],["$","div",null,{"className":"text-right","children":[["$","p",null,{"className":"text-sm text-slate-300","children":["A$","0.00"]}],["$","p",null,{"className":"text-xs font-semibold text-red-400","children":["-33.0","% 1Y"]}]]}]]}],["$","p",null,{"className":"mt-4 text-sm text-slate-400","children":"Adalta Limited is a clinical-stage biotechnology company developing its proprietary i-body technology platform for treating a range of diseases. Based in Australia, its lead product candidate, AD-214, is being developed to treat Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases."}],["$","div",null,{"className":"mt-4 flex items-center justify-between text-xs text-slate-500","children":[["$","span",null,{"children":["Market cap ","A$13M"]}],["$","span",null,{"className":"text-blue-300","children":"View analysis"}]]}]]}]]}]]}]]}]]}]]}]],null],null]},["$","$L4",null,{"parallelRouterKey":"children","segmentPath":["children","asx","children","$5","children"],"error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L6",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":"$undefined","notFoundStyles":"$undefined","styles":null}],null]},["$","$L4",null,{"parallelRouterKey":"children","segmentPath":["children","asx","children"],"error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L6",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":"$undefined","notFoundStyles":"$undefined","styles":null}],null]},[["$","html",null,{"lang":"en","className":"__variable_6d343d __variable_49a339","children":[["$","head",null,{"children":["$","link",null,{"rel":"icon","href":"/logo.svg","type":"image/svg+xml"}]}],["$","body",null,{"className":"min-h-screen bg-ink-900 text-slate-100","children":["$","div",null,{"className":"min-h-screen","children":[["$","header",null,{"className":"sticky top-0 z-50 border-b border-white/10 bg-ink-800/80 backdrop-blur","children":[["$","div",null,{"className":"mx-auto flex w-full max-w-6xl items-center justify-between px-4 py-4 sm:px-6 lg:px-8","children":[["$","$L3",null,{"href":"/","className":"flex items-center gap-3","children":[["$","$L7",null,{"src":"/logo.svg","alt":"ASX Desk","width":140,"height":40,"className":"h-10 w-auto","priority":true}],["$","span",null,{"className":"hidden text-xs uppercase tracking-[0.2em] text-slate-400 sm:inline","children":"Research Terminal"}]]}],["$","nav",null,{"className":"hidden items-center gap-6 text-sm text-slate-300 md:flex","children":[["$","$L3","/",{"href":"/","className":"transition hover:text-white","children":"Home"}],["$","$L3","/screener",{"href":"/screener","className":"transition hover:text-white","children":"Screener"}],["$","$L3","/sectors",{"href":"/sectors","className":"transition hover:text-white","children":"Sectors"}],["$","$L3","/news",{"href":"/news","className":"transition hover:text-white","children":"News"}],["$","$L3","/ipos",{"href":"/ipos","className":"transition hover:text-white","children":"IPOs"}],["$","$L3","/compare",{"href":"/compare","className":"transition hover:text-white","children":"Compare"}],["$","$L3","/about",{"href":"/about","className":"transition hover:text-white","children":"About"}]]}],["$","div",null,{"className":"hidden items-center gap-3 md:flex","children":[["$","$L8",null,{}],["$","button",null,{"className":"rounded-full border border-blue-500/40 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-blue-200 shadow-glow transition hover:bg-blue-500/20","children":"Premium Research"}],["$","button",null,{"className":"rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white shadow-glow transition hover:bg-blue-400","children":"Open Account"}]]}]]}],["$","div",null,{"className":"flex items-center justify-between gap-3 border-t border-white/5 px-4 py-3 md:hidden","children":[["$","div",null,{"className":"flex-1","children":["$","$L8",null,{}]}],["$","$L3",null,{"href":"/screener","className":"shrink-0 text-xs text-blue-300","children":"Screener"}]]}]]}],["$","main",null,{"className":"mx-auto w-full max-w-6xl px-4 pb-20 pt-6 sm:px-6 lg:px-8","children":["$","$L4",null,{"parallelRouterKey":"children","segmentPath":["children"],"error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L6",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":["$","div",null,{"className":"flex min-h-[60vh] flex-col items-center justify-center text-center","children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.3em] text-blue-300","children":"404"}],["$","h1",null,{"className":"mt-3 font-display text-3xl font-semibold","children":"Page not found"}],["$","p",null,{"className":"mt-3 text-sm text-slate-400","children":"We couldn't locate that ASX page. Try searching a ticker or visit the homepage."}],["$","$L3",null,{"href":"/","className":"mt-6 rounded-full bg-blue-500 px-6 py-3 text-xs font-semibold uppercase tracking-wide text-white","children":"Back to Home"}]]}],"notFoundStyles":[],"styles":null}]}],["$","footer",null,{"className":"border-t border-white/10 bg-ink-800/60","children":[["$","div",null,{"className":"mx-auto grid w-full max-w-6xl gap-8 px-4 py-12 sm:px-6 lg:grid-cols-3 lg:px-8","children":[["$","div",null,{"children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"ASX Desk"}],["$","p",null,{"className":"mt-3 text-sm text-slate-400","children":"Automated ASX stock research with AI-generated analysis, sector trends, and data-backed screening tools."}],["$","div",null,{"className":"mt-4 flex gap-3","children":[["$","button",null,{"className":"rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Open an Account"}],["$","button",null,{"className":"rounded-full border border-white/10 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-slate-300","children":"Download Media Kit"}]]}]]}],["$","div",null,{"className":"grid grid-cols-2 gap-6 text-sm text-slate-400","children":[["$","div",null,{"children":[["$","h4",null,{"className":"mb-2 font-semibold text-slate-200","children":"Platform"}],["$","ul",null,{"className":"space-y-2","children":[["$","li",null,{"children":["$","$L3",null,{"href":"/screener","className":"hover:text-white","children":"Screener"}]}],["$","li",null,{"children":["$","$L3",null,{"href":"/news","className":"hover:text-white","children":"News & Commentary"}]}],["$","li",null,{"children":["$","$L3",null,{"href":"/about","className":"hover:text-white","children":"About"}]}]]}]]}],["$","div",null,{"children":[["$","h4",null,{"className":"mb-2 font-semibold text-slate-200","children":"Sectors"}],["$","ul",null,{"className":"space-y-2","children":[["$","li",null,{"children":["$","$L3",null,{"href":"/sectors/materials","className":"hover:text-white","children":"Materials"}]}],["$","li",null,{"children":["$","$L3",null,{"href":"/sectors/financials","className":"hover:text-white","children":"Financials"}]}],["$","li",null,{"children":["$","$L3",null,{"href":"/sectors/health care","className":"hover:text-white","children":"Health Care"}]}],["$","li",null,{"children":["$","$L3",null,{"href":"/sectors/information technology","className":"hover:text-white","children":"Information Tech"}]}],["$","li",null,{"children":["$","$L3",null,{"href":"/sectors/energy","className":"hover:text-white","children":"Energy"}]}]]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h4",null,{"className":"font-semibold","children":"Weekly Alpha Briefing"}],["$","p",null,{"className":"mt-2 text-sm text-slate-400","children":"Get our AI-powered watchlist, sector heatmaps, and new ASX coverage in your inbox."}],["$","div",null,{"className":"mt-4 flex flex-col gap-3 sm:flex-row","children":[["$","input",null,{"type":"email","placeholder":"you@example.com","className":"w-full rounded-full border border-white/10 bg-ink-900/60 px-4 py-2 text-sm text-white placeholder:text-slate-500"}],["$","button",null,{"className":"rounded-full bg-blue-500 px-5 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Subscribe"}]]}],["$","p",null,{"className":"mt-3 text-xs text-slate-500","children":"By subscribing you agree to receive marketing updates. Unsubscribe anytime."}]]}]]}],["$","div",null,{"className":"border-t border-white/10 py-6 text-center text-xs text-slate-500","children":["$","p",null,{"children":"General advice only. This site does not consider your objectives, financial situation, or needs. Past performance is not indicative of future results."}]}]]}]]}]}]]}],null],null],[[["$","link","0",{"rel":"stylesheet","href":"/_next/static/css/5bd3404007bffd2a.css","precedence":"next","crossOrigin":"$undefined"}]],[null,"$L9"]]]]]
9:[["$","meta","0",{"name":"viewport","content":"width=device-width, initial-scale=1"}],["$","meta","1",{"charSet":"utf-8"}],["$","title","2",{"children":"PME share price, analysis & company profile - Pro Medicus Limited | ASX Desk"}],["$","meta","3",{"name":"description","content":"Latest PME share price overview, what Pro Medicus Limited does, bull and bear cases, and AI-powered analysis for ASX investors."}],["$","link","4",{"rel":"canonical","href":"https://asxdesk.com/asx/PME/"}],["$","meta","5",{"property":"og:title","content":"PME share price, analysis & company profile - Pro Medicus Limited"}],["$","meta","6",{"property":"og:description","content":"Latest PME share price overview, what Pro Medicus Limited does, bull and bear cases, and AI-powered analysis for ASX investors."}],["$","meta","7",{"property":"og:url","content":"https://asxdesk.com/asx/PME/"}],["$","meta","8",{"property":"og:type","content":"article"}],["$","meta","9",{"name":"twitter:card","content":"summary_large_image"}],["$","meta","10",{"name":"twitter:title","content":"PME share price, analysis & company profile - Pro Medicus Limited"}],["$","meta","11",{"name":"twitter:description","content":"Latest PME share price overview, what Pro Medicus Limited does, bull and bear cases, and AI-powered analysis for ASX investors."}],["$","meta","12",{"name":"next-size-adjust"}]]
1:null
